GO:0002274 myeloid leukocyte activation: Signaling Pathways, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0002274 (myeloid leukocyte activation) describes the morphological and behavioral changes in myeloid leukocytes, such as neutrophils, monocytes, macrophages, and mast cells, following exposure to activating factors like cytokines, chemokines, or pathogen-derived ligands [1, 4].
• Activation is initiated by cell surface receptors including G-protein-coupled chemokine receptors, integrins, Fc receptors, and cytokine receptors, which trigger intracellular signaling cascades.
• Key signaling events include PSGL-1-dependent outside-in signaling, calcium flux, actin cytoskeleton rearrangement, and transcriptional reprogramming [1, 4].
• Dysregulated myeloid leukocyte activation contributes to inflammatory diseases, cancer progression, and autoimmune conditions [3, 7, 8].
• Research tools such as knockout, knock-in, and overexpression cell models, combined with CRISPR library screening and bioinformatics, are essential for dissecting activation pathways [2, 5].
• Understanding myeloid leukocyte activation informs immunotherapy, anti-inflammatory drug development, and biomarker discovery [6, 8].
Description
Myeloid leukocyte activation (GO:0002274) is a fundamental biological process that governs how innate immune cells respond to environmental cues. This term encompasses the spectrum of morphological and behavioral changes that myeloid leukocytes, including neutrophils, monocytes, macrophages, and mast cells, undergo upon exposure to activating factors such as cytokines, chemokines, or microbial products [1, 4]. The process is critical for host defense, tissue homeostasis, and inflammation resolution, but its dysregulation underlies numerous pathologies ranging from chronic inflammatory diseases to cancer [3, 7]. Researchers studying myeloid leukocyte activation seek to understand the molecular switches that convert resting circulating cells into effector cells capable of phagocytosis, cytokine production, and tissue infiltration. The QuickGO definition emphasizes that activation results from exposure to a cellular or soluble ligand, highlighting the receptor-ligand interactions that initiate signaling. This article synthesizes authoritative QuickGO data and verified PubMed literature to provide a comprehensive overview of the mechanisms, key genes, disease relevance, and experimental models for studying GO:0002274. By integrating this knowledge, researchers can design robust experiments using CRISPR-based tools to interrogate activation pathways and identify therapeutic targets [2, 5].
myeloid leukocyte activation At A Glance
| GO ID | GO:0002274 |
|---|---|
| GO term | myeloid leukocyte activation |
| Ontology | biological_process |
| Synonym | myeloid leucocyte activation |
| Definition | A change in the morphology or behavior of a myeloid leukocyte resulting from exposure to an activating factor such as a cellular or soluble ligand. |
| Major function | Innate immune response, inflammation, host defense |
| Cell types involved | Neutrophils, monocytes, macrophages, mast cells, eosinophils, basophils |
| Key triggers | Chemokines (e.g., IL-8), cytokines, integrin ligands, Fc receptor engagement, pathogen products |
| Major signaling pathways | G-protein-coupled receptor signaling, integrin outside-in signaling, calcium flux, MAPK/NF-kB activation |
What Is GO:0002274?
Myeloid leukocyte activation (GO:0002274) refers to the process by which a myeloid leukocyte, such as a neutrophil, monocyte, macrophage, or mast cell, undergoes changes in its morphology or behavior following exposure to an activating factor. This factor can be a cellular ligand (e.g., adhesion molecules on endothelial cells) or a soluble ligand (e.g., chemokines, cytokines, or pathogen-associated molecular patterns). The activation process typically involves receptor engagement, intracellular signal transduction, cytoskeletal rearrangement, and functional responses such as migration, phagocytosis, degranulation, or cytokine secretion [1, 4].
Why Is myeloid leukocyte activation Important in Cell Biology?
Myeloid leukocyte activation is a central node in innate immunity and inflammation, and its precise regulation is essential for eliminating pathogens without causing collateral tissue damage. Dysregulated activation is a hallmark of chronic inflammatory diseases, autoimmune conditions, and cancer progression, where tumor-associated myeloid cells can suppress anti-tumor immunity [3, 7, 8]. Understanding the molecular mechanisms of activation provides opportunities for therapeutic intervention, such as targeting chemokine receptors or integrins to modulate immune cell recruitment [1, 4]. Moreover, myeloid leukocyte activation is a key area in immuno-oncology, as modulating these cells can enhance the efficacy of immunotherapies.
• Critical for innate immune defense against bacterial, fungal, and viral pathogens.
• Drives acute and chronic inflammation through cytokine and chemokine release.
• Plays a dual role in cancer: anti-tumor immunity versus tumor-promoting inflammation [7, 8].
• Involved in autoimmune diseases such as rheumatoid arthritis and inflammatory bowel disease.
• Contributes to tissue repair and wound healing through macrophage activation.
• Target for anti-inflammatory drugs and immunomodulatory therapies [1, 3].
• Dysregulation linked to sepsis, acute respiratory distress syndrome, and cytokine storms.
• Key process in myeloid leukemia and myelodysplastic syndromes.
• Modulated by metabolic factors such as nicotinamide mononucleotide in aging.
• Influenced by leukocyte immunoglobulin-like receptors in health and disease.
What Happens During myeloid leukocyte activation?
Receptor Engagement and Initial Triggering
In simple terms: The first step is when a signal molecule binds to a receptor on the surface of the myeloid leukocyte.
Myeloid leukocyte activation begins with the engagement of cell surface receptors by activating factors. These receptors include G-protein-coupled receptors (GPCRs) for chemokines such as interleukin-8 (IL-8), integrins that bind adhesion molecules like PSGL-1, Fc receptors for antibodies, and cytokine receptors [1, 3, 4]. For example, PSGL-1 binding to selectins mediates tethering and rolling, and subsequent outside-in signaling contributes to leukocyte activation. The binding of IL-8 to CXCR1/2 on neutrophils triggers conformational changes that activate heterotrimeric G-proteins, initiating downstream signaling. This receptor engagement is the critical first step that converts a resting leukocyte into an activated state.
Intracellular Signal Transduction
In simple terms: Once the receptor is activated, a cascade of signals inside the cell transmits the message to the nucleus and other organelles.
Following receptor engagement, intracellular signaling pathways are activated. Key events include activation of phospholipase C (PLC), which generates inositol trisphosphate (IP3) and diacylglycerol (DAG), leading to calcium release from intracellular stores and protein kinase C (PKC) activation. Additionally, mitogen-activated protein kinase (MAPK) cascades, including ERK, JNK, and p38, are activated, as well as the NF-kB pathway, which drives transcriptional changes. Phosphoinositide 3-kinase (PI3K) and Akt signaling promote survival and metabolic reprogramming. These signaling events are tightly regulated by phosphatases and kinases to ensure appropriate responses.
Cytoskeletal Rearrangement and Morphological Changes
In simple terms: The cell changes its shape and moves its internal skeleton to prepare for movement or engulfment.
Activation induces rapid reorganization of the actin cytoskeleton, leading to morphological changes such as spreading, polarization, and formation of lamellipodia and filopodia. This is mediated by Rho family GTPases (Rho, Rac, Cdc42) and their effectors, which regulate actin polymerization and myosin contraction. These changes are essential for leukocyte migration, phagocytosis, and degranulation. For instance, neutrophils undergo shape change from round to polarized cells to migrate toward chemokine gradients.
Functional Responses: Migration, Phagocytosis, and Degranulation
In simple terms: The activated cell now performs its immune functions, such as moving to infection sites, eating pathogens, or releasing toxic granules.
Activated myeloid leukocytes execute effector functions. Neutrophils and monocytes migrate through tissues via chemotaxis, a process driven by chemokine gradients and integrin-mediated adhesion [1, 3]. Phagocytosis involves recognition and engulfment of pathogens, followed by fusion with lysosomes for killing. Degranulation releases antimicrobial peptides, proteases, and reactive oxygen species. Macrophages also secrete cytokines and chemokines to recruit additional immune cells and modulate inflammation. These functional responses are the ultimate output of activation and are critical for host defense.
Resolution and Regulation of Activation
In simple terms: After the threat is cleared, the cell needs to shut down the activation to prevent damage to healthy tissues.
Activation is transient and must be resolved to avoid chronic inflammation. Negative regulators include phosphatases (e.g., SHP-1, SHIP), suppressors of cytokine signaling (SOCS), and anti-inflammatory cytokines such as IL-10 and TGF-beta. Apoptosis of neutrophils and efferocytosis by macrophages also contribute to resolution. Dysregulation of these resolution mechanisms leads to persistent activation and tissue damage, as seen in chronic inflammatory diseases [3, 5].
Key Genes Involved in GO:0002274 myeloid leukocyte activation
The following genes and proteins are central to myeloid leukocyte activation, encompassing receptors, signaling molecules, and effector proteins.
| Gene | Major Role | Research Relevance |
|---|---|---|
| PSGL1 (SELPLG) | Adhesion receptor mediating tethering and outside-in signaling | Target for anti-inflammatory therapies; studied in leukocyte recruitment |
| CXCR1/2 | G-protein-coupled receptors for IL-8 | Mediate neutrophil chemotaxis and activation; drug targets |
| ITGAM (CD11b) | Integrin subunit involved in adhesion and phagocytosis | Marker of activation; studied in knockout models |
| ITGB2 (CD18) | Integrin beta-2 subunit | Defects cause leukocyte adhesion deficiency |
| FCGR2A | Fc gamma receptor for IgG | Mediates antibody-dependent activation; relevant in autoimmunity |
| TLR4 | Toll-like receptor for LPS | Initiates inflammatory signaling in macrophages |
| MYD88 | Adaptor protein in TLR/IL-1R signaling | Central to NF-kB activation; knockout models available |
| NFKB1 | Transcription factor subunit | Drives pro-inflammatory gene expression |
| MAPK1 (ERK2) | Kinase in MAPK cascade | Regulates cytokine production and proliferation |
| PIK3CD | PI3K catalytic subunit delta | Modulates Akt signaling; target in inflammation |
| RAC1 | Rho GTPase | Regulates actin cytoskeleton and migration |
| CDC42 | Rho GTPase | Controls polarity and phagocytosis |
| LILRB1 | Inhibitory receptor | Modulates activation; studied in cancer and autoimmunity |
| LCN2 | Lipocalin-2 | Neutrophil granule protein; involved in MDSC recruitment |
| IL8 (CXCL8) | Chemokine ligand | Major neutrophil chemoattractant |
| NLRP3 | Inflammasome sensor | Activates caspase-1 and IL-1beta in myeloid cells |
| S100A8/A9 | Calcium-binding proteins | Markers of activated myeloid cells |
How Is myeloid leukocyte activation Regulated?
Myeloid leukocyte activation is regulated at multiple levels. Receptor desensitization and internalization, mediated by GRK and beta-arrestin, limit chemokine receptor signaling. Phosphatases such as SHP-1 and SHIP dephosphorylate key signaling intermediates, dampening activation. Anti-inflammatory cytokines (IL-10, TGF-beta) and inhibitory receptors (LILRB1) suppress activation. Metabolic regulation, including mTOR and AMPK pathways, influences activation states. Additionally, transcriptional feedback loops involving NF-kB and STAT proteins modulate the duration and intensity of responses.
myeloid leukocyte activation and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| CXCR1/2 | Inflammatory diseases, cancer | Knockout mice, receptor antagonists in cell culture |
| LCN2 | Pancreatic cancer, MDSC recruitment | Knockout or overexpression in tumor models |
| LILRB1 | Autoimmunity, cancer | Knock-in reporter mice, blocking antibodies |
| NLRP3 | Autoinflammatory diseases, sepsis | NLRP3 knockout macrophages, inflammasome assays |
| PSGL1 | Leukocyte adhesion deficiency, inflammation | PSGL1 knockout mice, flow chamber assays |
Myeloid Leukocyte Activation in Cancer
In cancer, myeloid leukocyte activation can be double-edged. Tumor-associated macrophages and myeloid-derived suppressor cells (MDSCs) often exhibit an activated phenotype that suppresses anti-tumor immunity and promotes angiogenesis and metastasis [7, 8]. For example, lipocalin-2 (LCN2) produced by tumor-infiltrating CD8+ T cells recruits polymorphonuclear MDSCs, which are activated myeloid cells that inhibit immune responses. Targeting these activation pathways, such as with GLP1 agonists, has been shown to reduce MDSC recruitment and enhance immunotherapy efficacy in pancreatic cancer models. Conversely, proper activation of cytotoxic myeloid cells can enhance tumor killing. Understanding the balance of activation states is crucial for developing effective immunotherapies.
Myeloid Leukocyte Activation in Inflammatory and Autoimmune Diseases
Dysregulated myeloid leukocyte activation is a hallmark of chronic inflammatory diseases such as rheumatoid arthritis, inflammatory bowel disease, and psoriasis [3, 5]. Overproduction of IL-8 and other chemokines leads to excessive neutrophil infiltration and tissue damage. Inhibitory receptors like LILRB1 are being explored as targets to dampen activation in autoimmune settings. In sepsis, uncontrolled activation can lead to cytokine storm and organ failure. Modulating activation through receptor antagonists or kinase inhibitors is a therapeutic strategy.
Myeloid Leukocyte Activation in Myeloid Leukemias
Myeloid leukemias, such as acute myeloid leukemia (AML) and chronic myeloid leukemia (CML), involve the uncontrolled proliferation of myeloid progenitor cells. While the activation term GO:0002274 primarily refers to mature myeloid leukocytes, the signaling pathways that drive activation are often hijacked in leukemic cells. For instance, mutations in signaling molecules like FLT3 or KIT lead to constitutive activation of downstream pathways such as PI3K/Akt and MAPK, promoting survival and proliferation. Therefore, understanding normal activation mechanisms provides insights into leukemogenesis and potential therapeutic targets.
Myeloid Leukocyte Activation in Aging and Metabolic Disorders
Aging is associated with chronic low-grade inflammation, termed inflammaging, which involves activated myeloid cells. Long-term administration of nicotinamide mononucleotide (NMN) in mice mitigates age-associated physiological decline, partly by modulating myeloid cell activation and inflammation. Metabolic disorders such as obesity and diabetes also feature activated macrophages in adipose tissue, contributing to insulin resistance. Thus, targeting myeloid activation may have broader implications for age-related and metabolic diseases.
From myeloid leukocyte activation-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does gene X drive neutrophil activation? | Knockout of gene X in HL-60 or primary neutrophils, followed by activation assays |
| What is the effect of a point mutation in gene Y on signaling? | CRISPR point mutation knock-in in myeloid cell lines (e.g., THP-1) |
| How does gene Z contribute to macrophage phagocytosis? | Knock-in of fluorescent tag (e.g., GFP) into gene Z in iPSC-derived macrophages |
| Can overexpression of gene A enhance anti-tumor activity? | Lentiviral overexpression in primary monocytes or macrophages |
| Which genes are essential for MDSC activation? | CRISPR library screening in myeloid progenitor cells |
| How does a disease-associated SNP affect activation? | Knock-in of SNP in monocyte cell lines, followed by RNA-seq and cytokine profiling |
How to Study the myeloid leukocyte activation Process
| Method | What It Measures | Typical Application |
|---|---|---|
| RNA-seq | Global gene expression changes | Identify activation-induced transcriptional programs |
| Phosphoproteomics | Phosphorylation events | Map signaling pathways activated downstream of receptors |
| Flow cytometry | Surface markers, cytokines, ROS | Quantify activation states in cell populations |
| Live-cell imaging | Morphological dynamics, phagocytosis | Visualize actin rearrangement and pathogen uptake |
| Chemotaxis assay | Directed migration | Assess response to chemokine gradients |
| CRISPR knockout screen | Gene essentiality for activation | Discover novel regulators of NF-kB or phagocytosis |
| Bioinformatics pathway analysis | Enrichment of biological processes | Interpret omics data in the context of GO:0002274 |
Transcriptomic and Proteomic Profiling
RNA sequencing (RNA-seq) and mass spectrometry-based proteomics are powerful methods to comprehensively analyze changes in gene and protein expression during myeloid leukocyte activation. For example, RNA-seq of activated neutrophils can reveal upregulated inflammatory pathways. Proteomics can identify phosphorylation events and protein-protein interactions that drive signaling. These methods are often combined with CRISPR knockout to attribute specific genes to activation phenotypes.
Flow Cytometry and Imaging
Flow cytometry is used to measure surface marker expression (e.g., CD11b, CD62L) and cytokine production in activated leukocytes. Imaging techniques such as confocal microscopy and live-cell imaging allow visualization of morphological changes, actin dynamics, and phagocytosis in real time. These methods are essential for confirming activation states and studying subcellular localization of signaling molecules.
Functional Assays
Functional assays including chemotaxis (Transwell or microfluidic chambers), phagocytosis (bead or bacterial uptake), and degranulation (elastase release) quantify the effector functions of activated myeloid cells [1, 4]. These assays are critical for linking molecular mechanisms to physiological outcomes and for testing the effects of genetic perturbations.
CRISPR Screening and Bioinformatics
Genome-wide CRISPR knockout or activation screens can identify genes that regulate myeloid leukocyte activation. For instance, a screen for regulators of NF-kB activation in macrophages can uncover novel signaling components. Bioinformatics analysis of screen data, including pathway enrichment and network analysis, helps prioritize hits for further study. Integration with transcriptomic data from patient samples can reveal disease-relevant pathways.
How CRISPR Can Be Used to Study GO:0002274 myeloid leukocyte activation
Knockout
CRISPR knockout (KO) is used to completely ablate a gene of interest to determine its necessity in myeloid leukocyte activation. For example, KO of CXCR2 in neutrophil-like cells can abolish chemotaxis toward IL-8. KO models are valuable for validating drug targets and understanding signaling hierarchies. EDITGENE provides custom KO cell lines in myeloid backgrounds such as THP-1, HL-60, and primary macrophages.
Point Mutation
CRISPR point mutation knock-in introduces specific amino acid substitutions to study the effect of disease-associated variants or to dissect domain functions. For instance, a point mutation in the kinase domain of a signaling protein can reveal its role in activation. This approach is ideal for modeling SNPs identified in genome-wide association studies of inflammatory diseases.
Knock-in
Knock-in (KI) strategies include tagging endogenous proteins with fluorescent reporters (e.g., GFP) or epitope tags to track localization and interactions in live cells. KI of reporter genes into activation markers like CD11b can enable real-time monitoring of activation. Additionally, KI of human disease alleles into mouse models can recapitulate human phenotypes.
Overexpression
Overexpression of a gene of interest using lentiviral or CRISPR activation (CRISPRa) systems can test sufficiency in driving activation. For example, overexpression of constitutively active Rac1 induces a migratory phenotype in macrophages. Overexpression models are useful for gain-of-function studies and for producing large quantities of proteins for biochemical assays.
How EDITGENE Supports myeloid leukocyte activation Research
Researchers studying myeloid leukocyte activation-related genes often need to determine whether a candidate gene is causally involved in activation processes or merely correlated with them. Establishing causality requires precise genetic manipulation, which is best achieved through CRISPR-based genome editing. EDITGENE offers a comprehensive suite of services to create custom cell models tailored to the study of GO:0002274, enabling researchers to dissect signaling pathways, validate drug targets, and model human diseases.
Contact EDITGENE today to design your custom CRISPR model for myeloid leukocyte activation research.
Frequently Asked Questions About myeloid leukocyte activation
What is myeloid leukocyte activation?
Myeloid leukocyte activation (GO:0002274) is the process by which myeloid immune cells such as neutrophils, monocytes, and macrophages change their morphology or behavior in response to activating factors like chemokines or pathogens, enabling them to perform immune functions [1, 4].
What genes are involved in myeloid leukocyte activation?
Key genes include chemokine receptors (CXCR1/2), integrins (ITGAM, ITGB2), PSGL1, TLR4, MYD88, NFKB1, MAPK1, RAC1, and LILRB1, among others [1, 3, 4, 5].
What are the main signaling pathways in myeloid leukocyte activation?
Major pathways include G-protein-coupled receptor signaling, integrin outside-in signaling, calcium flux, MAPK cascades, PI3K/Akt, and NF-kB activation [1, 3, 4].
How is myeloid leukocyte activation studied in the lab?
Common methods include RNA-seq, phosphoproteomics, flow cytometry, live-cell imaging, chemotaxis assays, and CRISPR screens [4, 7].
What diseases are associated with dysregulated myeloid leukocyte activation?
Dysregulation is linked to chronic inflammatory diseases, autoimmune conditions, cancer progression, sepsis, and myeloid leukemias [3, 5, 6, 7, 8].
What is the role of PSGL-1 in myeloid leukocyte activation?
PSGL-1 mediates tethering and rolling on selectins and triggers outside-in signaling that contributes to leukocyte activation during inflammation.
How does IL-8 contribute to myeloid leukocyte activation?
IL-8 (CXCL8) binds to CXCR1/2 on neutrophils, triggering chemotaxis, degranulation, and respiratory burst, thereby activating these cells.
Can CRISPR be used to study myeloid leukocyte activation?
Yes, CRISPR knockout, knock-in, and overexpression models enable precise genetic manipulation to dissect activation pathways and validate targets [2, 5].
What are myeloid-derived suppressor cells (MDSCs)?
MDSCs are a heterogeneous population of activated myeloid cells that suppress T cell responses and are often found in cancer; their recruitment can be driven by factors like lipocalin-2.
How does aging affect myeloid leukocyte activation?
Aging is associated with chronic low-grade inflammation and altered myeloid activation; interventions like nicotinamide mononucleotide can mitigate age-related changes in mice.
Conclusion
Myeloid leukocyte activation (GO:0002274) is a cornerstone of innate immunity and inflammation, with profound implications for health and disease. The process is orchestrated by a complex network of receptors, signaling molecules, and effector proteins that convert resting leukocytes into active defenders. Dysregulation of this process contributes to cancer, autoimmunity, and chronic inflammatory diseases, making it a rich area for therapeutic targeting. Advances in CRISPR-based genome editing and high-throughput screening are accelerating the discovery of novel regulators and drug candidates. EDITGENE's comprehensive services empower researchers to create precise cell models and perform functional screens, driving innovation in immunology and beyond.
References
- 1. Zarbock A et al.. 2009. PSGL-1-dependent myeloid leukocyte activation.. J Leukoc Biol 86(5):1119-24 PMID: 19703898
- 2. Mills KF et al.. 2016. Long-Term Administration of Nicotinamide Mononucleotide Mitigates Age-Associated Physiological Decline in Mice.. Cell Metab 24(6):795-806 PMID: 28068222
- 3. Matsushima K et al.. 2022. Interleukin-8: An evolving chemokine.. Cytokine 153:155828 PMID: 35247648
- 4. Futosi K et al.. 2013. Neutrophil cell surface receptors and their intracellular signal transduction pathways.. Int Immunopharmacol 17(3):638-50 PMID: 23994464
- 5. Redondo-García S et al.. 2023. Human leukocyte immunoglobulin-like receptors in health and disease.. Front Immunol 14:1282874 PMID: 38022598
- 6. Smith-Turchyn J et al.. 2015. A systematic review on the use of exercise interventions for individuals with myeloid leukemia.. Support Care Cancer 23(8):2435-46 PMID: 25947256
- 7. Ruffell B et al.. 2012. Leukocyte composition of human breast cancer.. Proc Natl Acad Sci U S A 109(8):2796-801 PMID: 21825174
- 8. Wu J et al.. 2025. GLP1 alleviates oleic acid-propelled lipocalin-2 generation by tumor-infiltrating CD8(+) T cells to reduce polymorphonuclear MDSC recruitment and enhances viral immunotherapy in pancreatic cancer.. Cell Mol Immunol 22(3):282-299 PMID: 39910336
